Learn about the design and outcomes of the EVOLVE-MS-2 trial, a Phase 3 study designed to assess gastrointestinal tolerability in patients treated with diroximel fumarate versus dimethyl fumarate over 5 weeks.

Biogen-107547.
Date of preparation: June 2021.